Danaher Corporation
NYSE:DHRMedical - Diagnostics & Research
-$0.38 today
- Market cap
- $160.69B
- Beta
- 0.83
- P/E (TTM)
- 34.0
- EPS (TTM)
- $5.21
- Dividend yield
- 0.77%
Volume 2.92M
Average 4.52M
DHR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Danaher CorporationNYSE: DHR
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $433M rose 14.6% year over year, ahead of the +4.2% change in trailing-twelve-month research & development. Sequentially, it rose 5.1% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.
Context
- Research & development amounted to 6.5% of revenue in FY2025, down 0.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +14.6% holds above the trailing-twelve-month pace of +4.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.6B USD
- Year-over-year change
- +0.9%
- 4-year CAGR
- -2.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.6B | +0.9% |
| FY2024 | 2024-12-31 | 1.58B | +5.4% |
| FY2023 | 2023-12-31 | 1.5B | -1.6% |
| FY2022 | 2022-12-31 | 1.53B | -12.3% |
| FY2021 | 2021-12-31 | 1.74B | — |
Research & Development vs competitors
How DHR compares with its peers on the latest reported figures
- DHR's LTM Sep 2026 research & development of $1.67B is the highest of the 9 companies compared; the peer median is $357.62M.
- Its year-over-year change of +4.2% is the 6th highest of 9, against a peer median of +5.3%.
- Research & development amounts to 6.5% of revenue for DHR, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.67B | +4.2% | +1.5% | 6.5% | |
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jun 2026 | $958M | -3.4% | -10.4% | 21.3% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jun 2026 | $393.5M | -1.6% | +18.8% | 11.2% | |
| LTM Jul 2026 | $321.75M | +71.7% | +3.5% | 6.9% | |
| LTM Jul 2026 | $215.83M | +5.2% | -0.9% | 7.4% | |
| LTM Jun 2026 | $208.01M | +7.9% | +4.0% | 5.0% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| Peer median (excluding DHR) | $357.62M | +5.3% | -0.6% | 7.2% | |
Competitors are the stored peer set for DHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.45B | 26.64B | 23.89B | 23.88B | 24.57B |
| Cost of Revenue | 11.5B | 10.46B | 9.86B | 9.67B | 9.6B |
| Gross Profit | 17.95B | 16.19B | 14.03B | 14.21B | 14.97B |
| Gross Margin | 61.0% | 60.8% | 58.7% | 59.5% | 60.9% |
| Research & Development | 1.74B | 1.53B | 1.5B | 1.58B | 1.6B |
| Selling, General & Admin | 8.16B | 7.12B | 7.25B | 7.44B | 8.24B |
| Operating Expenses | 9.9B | 8.65B | 8.76B | 9.02B | 9.83B |
| Depreciation & Amortization | 2.17B | 2.13B | 2.17B | 2.35B | 2.45B |
| EBITDA | 10.01B | 9.49B | 7.5B | 7.28B | 6.95B |
| EBITDA Margin | 34.0% | 35.6% | 31.4% | 30.5% | 28.3% |
| Operating Income | 8.05B | 7.54B | 5.28B | 5.18B | 5.14B |
| Operating Margin | 27.3% | 28.3% | 22.1% | 21.7% | 20.9% |
| Interest Income | 11M | 41M | 303M | 117M | 30M |
| Interest Expense | 241M | 207M | 289M | 278M | 265M |
| Other Income / Expenses | (452M) | (390M) | (235M) | (538M) | (904M) |
| Income Before Tax | 7.6B | 7.15B | 5.04B | 4.65B | 4.23B |
| Pre-Tax Margin | 25.8% | 26.8% | 21.1% | 19.5% | 17.2% |
| Income Tax Expense | 1.25B | 818M | 823M | 747M | 619M |
| Net Income | 6.43B | 7.21B | 4.76B | 3.9B | 3.61B |
| Net Margin | 21.8% | 27.1% | 19.9% | 16.3% | 14.7% |
| EPS (Basic) | 8.77 | 9.80 | 6.44 | 5.33 | 5.07 |
| EPS (Diluted) | 8.61 | 9.64 | 6.38 | 5.29 | 5.04 |
| Weighted Avg Shares | 714.6M | 725.1M | 736.5M | 731M | 707.3M |
| Weighted Avg Shares (Diluted) | 736.8M | 737.1M | 743.1M | 737.2M | 711M |
Danaher Corporation
NYSE:DHR
Intrinsic Alpha fair value
Locked
Current Price
$228.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.